Biogen has declared its intention to purchase Apellis Pharmaceuticals for approximately $5.6 billion, a deal inclusive of a contingent value right. This acquisition marks a significant strategic move for Biogen, aiming to incorporate Apellis's innovative complement C3 therapies, EMPAVELI and SYFOVRE, into its existing pharmaceutical offerings. This expansion is set to bolster Biogen's footprint in immunology, rare disease treatment, and nephrology. Analysts anticipate that this transaction will not only enhance Biogen's revenue streams but also solidify its competitive standing in the market. The completion of this acquisition is slated for the second quarter of 2026, promising a new chapter for both companies in the biopharmaceutical landscape.
The announcement of Biogen's planned acquisition on Tuesday sent ripples through the stock market, with Apellis shares experiencing a remarkable surge of over 135% to roughly $40. Conversely, Biogen's stock saw a 5% decline, settling at $178. This significant transaction is valued at approximately $5.6 billion, where Apellis shareholders are set to receive $41 per share in cash. Additionally, they will be granted a non-transferable contingent value right (CVR), potentially worth up to $4 per share, contingent on the achievement of specific global sales milestones for SYFOVRE.
A key aspect of this acquisition is the integration of two already approved complement C3 therapies into Biogen’s product lineup: EMPAVELI, designed for rare kidney conditions, and SYFOVRE, targeting geographic atrophy linked to age-related macular degeneration. In 2025, these two products collectively generated $689 million in sales, with projections indicating a mid-to-high teen growth rate extending through at least 2028. This move is expected to significantly enhance Biogen's capabilities in treating a broader spectrum of diseases and reinforces its commitment to specialized therapeutic areas.
Biogen emphasized that this acquisition will broaden its involvement in immunology and rare diseases, while simultaneously reinforcing its nephrology division. Specifically, the deal is expected to accelerate the advancement of felzartamab, a drug currently undergoing Phase III trials for various kidney ailments. Jefferies, a notable financial firm, views this $5.6 billion acquisition as a strategically astute decision by Biogen. The firm highlighted that the transaction provides immediate revenue through EMPAVELI and SYFOVRE, while also laying the groundwork for future growth through pipeline developments like felzartamab.
From a financial standpoint, Jefferies projects that the transaction will contribute positively to Biogen's non-GAAP EPS beginning in 2027, and anticipates a reduction in debt by the close of 2027. The acquisition is also poised to diversify Biogen's revenue base, potentially adding an estimated $700 million to $1 billion annually through 2028. Analysts from Jefferies also noted that the deal will enhance Biogen's commercial readiness in the nephrology sector. They further commented that while current SYFOVRE sales are below the CVR milestone objectives, the introduction of a prefilled syringe and ongoing market expansion efforts could stimulate future growth. EMPAVELI is expected to solidify Biogen’s standing in nephrology, preparing the market for forthcoming product introductions such as felzartamab.
Jefferies characterized the deal as "multimodal," indicating its capacity to deliver both immediate financial benefits and a stronger strategic position for Biogen within the high-value rare disease markets. This comprehensive approach is designed to ensure sustainable growth and a competitive edge in a rapidly evolving pharmaceutical landscape. The impending closure of this transaction in the second quarter of 2026 is eagerly awaited as it promises to reshape Biogen's market presence and therapeutic offerings.
This strategic move underscores Biogen's dedication to expanding its therapeutic reach and solidifying its leadership in specialized medical fields. The integration of Apellis's innovative treatments is poised to create new opportunities for patient care and drive significant advancements in the biopharmaceutical industry. The transaction's successful completion will mark a pivotal moment for Biogen, positioning it for enhanced growth and impact in the coming years.